Waltham-based Deciphera Pharmaceuticals has announced it is being acquired by Japan’s ONO Pharmaceutical Company for $2.4 billion. Deciphera is focused on discovering, developing, and commercializing new cancer medicines and brings specialized R&D and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities. The acquisition is […]

Vertex has announced it plans to acquire Seattle biotech Alpine Immune Sciences for $65 per share or approximately $4.9 billion in cash. Alpine is focused on discovering and developing innovative, protein-based immunotherapies. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter. Alpine’s […]

Watertown clinical-stage biopharma Neumora Therapeutics’ Phase 1 trial of NMRA-266 has been placed on clinical hold by the FDA based on pre-clinical data showing convulsions in rabbits. Approximately 30 participants have been dosed in the Phase 1 study, with no evidence of convulsions observed in any participant. “We are disappointed with the unanticipated safety findings […]

Amylyx Pharmaceuticals has started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for its ALS drug and immediately remove the product from the market in both the U.S. and Canada. The drug is sold under the name Relyvrio in the U.S.and is also known as AMX0035. The decision is […]

Clinical-stage biotherapeutics company PureTech Health has launched Seaport Therapeutics with $100 million in an oversubscribed Series A financing. Seaport will focus on development of a pipeline of neuropsychiatric medicines created and initially developed at PureTech. Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis. Seaport […]